Literature DB >> 16520104

Adherence, patient preference and dosing frequency: understanding the relationship.

J Y Reginster1, V Rabenda, A Neuprez.   

Abstract

Adherence to treatment among patients with chronic diseases is currently suboptimal. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications and therefore increased healthcare costs. For patients with osteoporosis, long-term adherence to therapy is further complicated by the asymptomatic nature of the disease and the lack of options for patient self-monitoring. Bone densitometry and biochemical markers of bone turnover are assessments that could be used by physicians to provide feedback to patients on the effectiveness of medication. However, these feedback systems are costly and not readily available. Oral bisphosphonates are currently the first-line therapy for postmenopausal osteoporosis. However, they are associated with stringent dosing procedures, and some patients may experience upper gastrointestinal side-effects following administration. Alarmingly, approximately 50% of patients discontinue daily bisphosphonate therapy within 1 year, which negatively impacts upon treatment outcomes, leading to a reduced antifracture effect. Thus, there is a need for an effective therapy that enhances patient adherence. The impact of reducing bisphosphonate dosing frequency on therapeutic adherence has been documented in several studies. Data have shown that, although weekly dosing improves adherence compared with daily administration, levels are still suboptimal. Results from two recent studies that have assessed patient preference for a once-monthly compared with a weekly dosing schedule have demonstrated that patients prefer a monthly regimen (67-71%). Their reasons for preferring once-monthly dosing were that it would fit better with their lifestyle (49-77%) and would be more convenient (75%). A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520104     DOI: 10.1016/j.bone.2006.01.150

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  38 in total

1.  Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.

Authors:  Tae-Beom Kim; Khae-Hawn Kim; Sang-Jin Yoon
Journal:  Int Neurourol J       Date:  2010-04-30       Impact factor: 2.835

2.  Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study.

Authors:  Barbara Lukert; Sacha Satram-Hoang; Sally Wade; Mary Anthony; Guozhi Gao; Robert Downs
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 3.  Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

Authors:  S Lee; P Glendenning; C A Inderjeeth
Journal:  Osteoporos Int       Date:  2010-06-30       Impact factor: 4.507

4.  Adherence and weight loss outcomes associated with food-exercise diary preference in a military weight management program.

Authors:  Laura E Shay; Diane Seibert; Dorraine Watts; Tracy Sbrocco; Claire Pagliara
Journal:  Eat Behav       Date:  2009-07-16

5.  Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.

Authors:  E Michael Lewiecki
Journal:  Core Evid       Date:  2010-06-15

6.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

7.  Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.

Authors:  H Choi; J-H Kim; J-S Shim; J Y Park; S H Kang; D G Moon; J Cheon; J G Lee; J J Kim; J-H Bae
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

8.  Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid.

Authors:  Raj Carmona; Rick Adachi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.

Authors:  Yoon-Sok Chung; Sung-Kil Lim; Ho-Yeon Chung; In-Kyu Lee; Il-Hyung Park; Ghi-Su Kim; Yong-Ki Min; Moo-Il Kang; Dong-Jin Chung; Yong-Ki Kim; Woong Hwan Choi; Min Ho Shong; Ji-Hyun Park; Dong-Won Byun; Hyun-Koo Yoon; Chan Soo Shin; Yil-Seob Lee; Nam-Hee Kwon
Journal:  Calcif Tissue Int       Date:  2009-10-09       Impact factor: 4.333

10.  Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.

Authors:  Debby den Uyl; Piet P M M Geusens; Frank N R van Berkum; Harry H M L Houben; Max C Jebbink; Willem F Lems
Journal:  Clin Rheumatol       Date:  2009-12-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.